Fibronectin Protein, Human

Fibronectin binds collagen, fibrin, heparin, DNA, and actin. It is involved in cell adhesion, motility, opsonization, wound healing and maintenance of cell shape. Fibronectin Protein, Human is the recombinant human-derived Fibronectin protein, expressed by E. coli, with tag free.

Fibronectin, a versatile glycoprotein, plays a crucial role in cellular interactions by binding to various compounds such as collagen, fibrin, heparin, DNA, and actin. Its involvement in cell adhesion, motility, opsonization, wound healing, and maintenance of cell shape underscores its significance in fundamental cellular processes. Fibronectin also contributes to osteoblast compaction through the fibronectin fibrillogenesis cell-mediated matrix assembly process, essential for osteoblast mineralization, and regulates the deposition of type I collagen by osteoblasts. Acting as a ligand for the LILRB4 receptor, Fibronectin inhibits FCGR1A/CD64-mediated monocyte activation. Moreover, Fibronectin's ability to induce fibril formation, as observed in the fibronectin polymer named superfibronectin, imparts enhanced adhesive properties. Notably, both anastellin and superfibronectin exhibit inhibitory effects on tumor growth, angiogenesis, and metastasis, with anastellin activating p38 MAPK and inhibiting lysophospholipid signaling. The multifaceted functions of Fibronectin underscore its pivotal role in cellular dynamics and its potential as a target for therapeutic interventions in various pathological conditions.

Fibronectin protein (Human) (2-40 nM, 24-100 h) dose-dependently promotes the growth of mouse embryonic cells lacking endogenous fibronectin^[11].
Fibronectin protein (Human) has high binding affinity for the human LILRB4 receptor and its direct homolog gp49B receptor in mice, with K_D values of 421 nM and 50.1 nM, respectively^[12].

FN30-Fc is a recombinant protein formed by fusing the N-terminal 30 kDa fragment of human fibronectin (FN30) with mouse IgG2a Fc. FN30-Fc (200 μg, intraperitoneally injected into 10-week-old mice, a total of 2 doses with a 2-week interval) shows efficacy in improving autoimmune nephritis in the BXSB/Yaa lupus (SLE) mouse model^[12].

1.Measured by its ability to support cell attachment and spreading when used as a substratum for cell culture. The ED₅₀ for this effect is ≤ 385.7 ng/mL.
2.Measured by the ability of the immobilized protein to support the adhesion of B16-F1 mouse melanoma cells. The ED₅₀ for this effect is ≤182.9 ng/mL, corresponding to a specific activity is ≥5.467×10³ units/mg.

• 
  Measured by the ability of the immobilized protein to support the adhesion of B16-F1 mouse melanoma cells. The ED₅₀ for this effect is 124.5 ng/mL, corresponding to a specific activity is 8.03×10³ units/mg.

Human

E. coli

Tag Free

P02751-1 (P1270-S1546&A1721-T2016)

2335  [NCBI]

Partial

PTDLRFTNIGPDTMRVTWAPPPSIDLTNFLVRYSPVKNEEDVAELSISPSDNAVVLTNLLPGTEYVVSVSSVYEQHESTPLRGRQKTGLDSPTGIDFSDITANSFTVHWIAPRATITGYRIRHHPEHFSGRPREDRVPHSRNSITLTNLTPGTEYVVSIVALNGREESPLLIGQQSTVSDVPRDLEVVAATPTSLLISWDAPAVTVRYYRITYGETGGNSPVQEFTVPGSKSTATISGLKPGVDYTITVYAVTGRGDSPASSKPISINYRTEIDKPS&AIPAPTDLKFTQVTPTSLSAQWTPPNVQLTGYRVRVTPKEKTGPMKEINLAPDSSSVVVSGLMVATKYEVSVYALKDTLTSRPAQGVVTTLENVSPPRRARVTDATETTITISWRTKTETITGFQVDAVPANGQTPIQRTIKPDVRSYTITGLQPGTDYKIYLYTLNDNARSSPVVIDASTAIDAPSNLRFLATTPNSLLVSWQPPRARITGYIIKYEKPGSPPREVVPRPRPGVTEATITGLEPGTEYTIYVIALKNNQKSEPLIGRKKTDELPQLVTLPHPNLHGPEILDVPST

Approximately 63 kDa

• 
  Greater than 95% as determined by reducing SDS-PAGE.

Lyophilized powder

Lyophilized from a 0.2 μm filtered solution of 12.5 mM Sodium Citrate, 1.25% Sucrose, pH 5.5 or PBS, pH 6.8, 5% trehalose, 5% mannitol and 0.01% Tween 80.

<0.01 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.

• [1]. Patten J, Wang K. Fibronectin in development and wound healing. Adv Drug Deliv Rev. 2021 Mar;170:353-368.  [Content Brief]

  [2]. Lenselink EA. Role of fibronectin in normal wound healing. Int Wound J. 2015 Jun;12(3):313-6. doi: 10.1111/iwj.12109. Epub 2013 Jun 7.  [Content Brief]

  [3]. Bielefeld K A, et al. Fibronectin and β-catenin act in a regulatory loop in dermal fibroblasts to modulate cutaneous healing[J]. Journal of Biological Chemistry, 2011, 286(31): 27687-27697.  [Content Brief]

  [4]. Shi F, et al. MT1-MMP regulates the turnover and endocytosis of extracellular matrix fibronectin[J]. Journal of cell science, 2011, 124(23): 4039-4050.  [Content Brief]

  [5]. Lefcort F, et al. Regulation of expression of fibronectin and its receptor, α5β1, during development and regeneration of peripheral nerve[J]. Development, 1992, 116(3): 767-782.

  [6]. Clark RA, et al. Blood vessel fibronectin increases in conjunction with endothelial cell proliferation and capillary ingrowth during wound healing. J Invest Dermatol. 1982 Nov;79(5):269-76.  [Content Brief]

  [7]. Oyama F, et al. Deregulation of alternative splicing of fibronectin pre-mRNA in malignant human liver tumors. J Biol Chem. 1989 Jun 25;264(18):10331-4.  [Content Brief]

  [8]. Yi M, Ruoslahti E. A fibronectin fragment inhibits tumor growth, angiogenesis, and metastasis. Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):620-4.  [Content Brief]

  [9]. Quirós J, et al. Beneficial effect of fibronectin administration on chronic nephritis in rats. Arthritis Rheum. 1990 May;33(5):685-92.  [Content Brief]

  [10]. Su MT, et al. Blockade of checkpoint ILT3/LILRB4/gp49B binding to fibronectin ameliorates autoimmune disease in BXSB/Yaa mice. Int Immunol. 2021 Jul 23;33(8):447-458.  [Content Brief]

  [11]. Sottile J, et al. Fibronectin matrix assembly enhances adhesion-dependent cell growth. J Cell Sci. 1998 Oct;111 ( Pt 19):2933-43.  [Content Brief]